Bevacizumab is a type of drug called a monoclonal antibody. These drugs are sometimes called targeted therapies. They work by ‘targeting’ specific proteins (receptors) on the surface of cells.
Bevacizumab targets a protein called vascular endothelial growth factor (VEGF) that helps cancer cells grow a new blood supply.
Targeting VEGF reduces the supply of oxygen and nutrients so that the tumour shrinks or stops growing.